Documentdetail
ID kaart

oai:pubmedcentral.nih.gov:9314...

Onderwerp
Regular Issue Articles
Auteur
Xu, Yaqian Feeney, Megan P. Surface, Matthew Novak, Dan Troche, Michelle S. Beck, James C. Alcalay, Roy N.
Langue
en
Editor

John Wiley & Sons, Inc.

Categorie

Wiley-Blackwell Online Open

Jaar

2022

vermelding datum

01-12-2023

Trefwoorden
survey parkinson disease
Metriek

Beschrijving

BACKGROUND: Telehealth has been widely adopted in providing Parkinson's disease care during the coronavirus disease 2019 pandemic.

OBJECTIVE: The aim of this study was to survey people living with Parkinson's disease (PwPD) about their attitudes toward and utilization of telehealth services.

METHODS: A survey was administered to PwPD via Parkinson's Foundation and Columbia University mailing lists.

RESULTS: Of 1,163 responses, 944 complete responses were analyzed.

Telehealth awareness was 90.2% (850/942), and utilization was 82.8% (780/942).

More than 40% of PwPD were equally or more satisfied with telehealth compared with in‐person visits in all types of services used.

The highest satisfaction was observed in speech‐language pathology appointments (78.8%, 52/66) followed by mental health services (69.2%, 95/137).

CONCLUSIONS: In selected circumstances and indications, such as speech‐language pathology and mental health services, telehealth may be a useful tool in the care of PwPD beyond the coronavirus disease 2019 pandemic.

© 2022 The Authors.

Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

Xu, Yaqian,Feeney, Megan P.,Surface, Matthew,Novak, Dan,Troche, Michelle S.,Beck, James C.,Alcalay, Roy N., 2022, Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study, John Wiley & Sons, Inc.

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw